Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.
The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback